Modal close

Hi there,

You turn to Democracy Now! for ad-free news you can trust. This weekend, we're broadcasting live from D.C. as students and people of all ages converge on the capital to demand action on gun control. Our coverage is produced at a fraction of the cost of a commercial news operation, without ads, paywalls, government funds or corporate sponsors. How is this possible? Only with your support. If you and everyone visiting this website gave just $4, it would cover our operating costs for 2018. Pretty exciting, right? Please do your part. It takes just a few minutes to make sure that Democracy Now! is there for you and everybody else.

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.


Bio-Terrorism–a Phantom Menace?

StorySeptember 25, 2000
Default content image
Close circle
Media Options

Last week the US Center for Disease Control and Prevention awarded Oravax, a biotechnology company in Cambridge, MA, a contract to produce 40 million doses of vaccine against smallpox. The potentially fatal disease has been eradicated since 1977, but the 20-year, $343 million contract calls to create a stockpile of the vaccine to be used by civilians in the event of a bio-terrorist attack.

Last week’s Financial Times reported that “US defense officials have long feared that laboratory samples of smallpox might have fallen into the hands of potential terrorists or rogue states. Samples have been stored in laboratories in the US and Russia.

Attention was refocused on smallpox in the early 1990s after a Soviet defector told US authorities that Moscow had a big bio-warfare program, including smallpox.”

Since 1996 federal spending on counter-terrorism has nearly doubled to $11 billion a year. Yet to date, there has not been a single documented incident involving bioterrorism in the US. And many arms control officials and scientists say the chances of such an attack are close to zero.

When we asked the CDC why the vaccine was being made now, they said that the directive came to them as a national priority.


  • James W. LeDuc, Acting Director of the Division of Viral and Rickettsial Diseases at the Center for Disease Control and Prevention in Atlanta.
  • Lance Gordon, Executive Vice President of Orivax
  • Robert Dreyfuss, a contributing writer to Mother Jones Magazine, and an independent journalist. His article, “The Phantom Menace; With the Cold War over, Washington is spending billions to prevent a doomsday attack by foreign terrorists. But just how real is the threat?” appeared in this month’s issue of Mother Jones Magazine.

Related Story

Video squareStoryMar 15, 2018Remembering Courtlin Arrington: The Victim of a Recent School Shooting Largely Ignored by Media
The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.
Make a donation
Up arrowTop